PROGRESSIVE MS TRIALS
updated September 2013

Abbreviations Key:
AAN – American Academy of Neurology
CP – chronic progressive
ECTRIMS – European Committee of Treatment and Research in MS
IM – intramuscular, injected into muscle
IV – intravenous, injected into vein
PP - primary progressive
PR - progressive relapsing
RR - relapsing-remitting
SC – subcutaneous, injected under the skin
SP - secondary progressive

AGENT	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW DRUG IS TAKEN	TYPE OF MS/ NUMBER OF SUBJECTS	RESULTS
Cannabis extract (dronabinol)	To determine ability to prevent disease progression, also known as CUPID trial	May reduce neuronal damage through interaction with cannabinoid and opioid receptors	oral	PP, SP/493	Did not stop progression, brain atrophy, or new lesions; analysis of subgroup suggested possible benefit in those with milder disability; read more http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=8055.
Cyclophos-phamide vs. methylpred-nisolone	To control disease progression, also known as PROMESS study	Interferes with proliferating immune cells (cyclophosphamide)/Closes blood-brain barrier, anti-inflammatory (methylprednisolone)	IV	SP/360	Results expected later this year, per communication with primary investigator; read more http://clinicaltrials.gov/ct2/show/NCT00241254.

AGENT	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW DRUG IS TAKEN	TYPE OF MS/ NUMBER OF SUBJECTS	RESULTS
Epigallocate chin-gallate (Sunphenon ®, Taiyo International Food)	To determine effects on brain tissue volume loss	May interfere with T cell growth and function, and protect against neuronal injury (Sunphenon)	oral	SP, PP/60	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT00799890.
Estriol	To improve cognition	May improve nerve impulse transmission.	Oral	RR,SP,PP/64	Ongoing, read more http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=8115.
Fingolimod (Gilenya™, Novartis)	To test safety and effective-ness, also known as INFORMS study	Sphingosine-1-phosphate receptor binder; prevents lymphocytes from exiting lymphatic tissue	oral	PP/654	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT00731692.
Idebenone	To determine effect on disease activity	Acts as a potent antioxidant and facilitates mitochondrial electron flux and energy production; potentially anti-inflammatory	oral	PP/80	Ongoing, read more http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=4502.
Lipoic acid	To determine ability to protect brain, slow disability	Activates cAMP signaling pathways	oral	SP/56	Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01188811.

AGENT	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW DRUG IS TAKEN	TYPE OF MS/ NUMBER OF SUBJECTS	RESULTS
Masitinib (AB Science)	To determine safety and effectiveness in reducing disease activity	Inhibits the survival, migration and activity of mast cells	oral	SP,PP/450	Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01433497.
MIS416 (Innate Thera-peutics Limited)	To examine safety	A construct of microparticle and naturally occurring, non-immunogenic, cytosolically-active TLR-9 and NOD-2 ligands	IV	CP/24	Safe and well tolerated (Abstract #p1095); read more (cut and paste this link) http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=158369&XNSPRACHE_ID=2&XNKONGRESS_ID=171&XNMASKEN_ID=900. This trial is cofunded by the National MS Society's drug development subsidiary, FastForward; read more here http://www.nationalmssociety.org/fast-forward/who-weve-funded/download.aspx?id=23235.
Mesen-chymal stem cells	To assess safety, feasibility, tolerability	May inhibit immune mechanisms and augment intrinsic tissue repair	IV	RR,SP,PR/24	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT00813969.

AGENT	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW DRUG IS TAKEN	TYPE OF MS/ NUMBER OF SUBJECTS	RESULTS
MS SMART (three therapies with nerve-protecting potential: Ibudilast, Amiloride, and Riluzole)	To slow or stop MS pro-gression	May protect nerves from damage	Oral	SP/350	Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01910259.
Natalizumab (Tysabri®, Biogen Idec and Elan)	To determine effectiveness in reducing disability progression, also known as ASCEND study	Interferes with movement of immune cells across the blood-brain barrier by attaching to alpha 4-integrin	IV	SP/856	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT01416181.
Ocrelizumab (Hoffmann-La Roche)	To evaluate safety and effectiveness in reducing disease activity, also known as ORATORIO study	Binds to CD20 antigen on B cells and induces B-cell lysis	IV	PP/630	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT01194570.
Oxcar-bazepine	To evaluate ability to slow progression, also known as PROXIMUS study	May reduce nerve damage	Oral	SP/	Ongoing. The National MS Society is funding a study of a possible biomarker for the success of neuroprotective therapies within this trial.

AGENT	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW DRUG IS TAKEN	TYPE OF MS/ NUMBER OF SUBJECTS	RESULTS
Rehab-ilitation (constraint-induced movement therapy)	To rehabilitate extremity use	Physical therapy aimed at impaired arm believed to cause growth in brain regions to improve use	Ex-ercise	RR,SP,PP/66	Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01081275.
Rituximab	To evaluate the safety and effectiveness of intravenous and intrathecal rituximab, also known as RIVITaLISe study	Binds to CD20 antigen on B cells and induces B-cell lysis	IV, intra-thecal	SP/80	Ongoing, read more http://clinicaltrials.gov/ct2/show/NCT01212094.
Siponimod	To evaluate safety and effectiveness	Sphingosine-1-phosphate receptor binder; prevents lymphocytes from exiting lymphatic tissue	oral	SP, 1530	Ongoing; read more http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7954.
TcelnaTM (imilecleucel-T, Opexa Therapeutics)	To determine effectiveness in reducing disability progression, also known as Abili-T study	Experimental T-cell treatment made with a person's own immune cells	subcutaneous	SP 180	Ongoing, read more http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7026.